Corteria

We are excited to announce that preclinical data on COR-1389, the first-in-class and best-in-class CRF2 receptor agonist, will be presented at EASD 2026 in Milan! COR-1389 is designed to deliver weight loss while increasing lean muscle mass, offering a fu

COR-1167 is entering Phase 2 clinical trial for the treatment of Worsening Heart Failure after obtaining promising Phase 1 data, while the Phase 1 of COR-1389 is ongoing for the treatment of Obesity and Right Heart Failure. Philip Janiak, Corteria's CEO s

At ESC HF 2024 in Lisbon, during an oral presentation, new data data of our CRF2 peptide agonist COR-1167 were released. On top of furosemide, COR-1167 reduced elevated cardiac filling and venous pressures, increased diuresis, decreased body weight and im